• Je něco špatně v tomto záznamu ?

Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study

G. Amarenco, M. Sutory, R. Zachoval, M. Agarwal, G. Del Popolo, R. Tretter, G. Compion, D. De Ridder,

. 2017 ; 36 (2) : 414-421. [pub] 20151229

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18017372

AIMS: To investigate the effect on urodynamics of 4 weeks treatment with solifenacin succinate in patients with neurogenic detrusor overactivity (NDO) due to multiple sclerosis (MS) or spinal cord injury (SCI). METHODS: SONIC was a prospective, multicenter, double-blind, phase 3b/4 study investigating the efficacy and safety of solifenacin 10 mg in patients with NDO due to MS or SCI. Patients (n = 189) were randomized to placebo or active treatment (solifenacin 5 mg, 10 mg or oxybutynin hydrochloride 15 mg) for 4 weeks, after a 2-week, single-blind, placebo run-in period. The primary endpoint was change in maximum cystometric capacity (MCC) from baseline to end of treatment. The primary analysis compared solifenacin 10 mg versus placebo; all other comparisons were considered secondary. Secondary endpoints included changes in urodynamic parameters, patient-reported outcomes, and safety assessments. RESULTS: In the primary analysis, solifenacin 10 mg significantly improved mean change from baseline MCC versus placebo (P < 0.001) and was associated with improvements in bladder volume at first contraction and at first leak as well as detrusor pressure at first leak. Similar results were obtained for oxybutynin versus placebo. Patient perception of bladder condition significantly improved with solifenacin 10 mg versus placebo (P = 0.041). There was a clear improvement in quality of life (QoL) in the solifenacin arms versus placebo. The overall incidence of adverse events was low. CONCLUSIONS: In patients with NDO due to MS and SCI, 4 weeks of treatment with solifenacin 10 mg improved urodynamic variables and QoL versus placebo and was well tolerated. Neurourol. Urodynam. 36:414-421, 2017. © 2015 Wiley Periodicals, Inc.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017372
003      
CZ-PrNML
005      
20180517140645.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/nau.22945 $2 doi
035    __
$a (PubMed)26714009
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Amarenco, G $u Hôpital Tenon, Service De Neuro-Urologie Et D'Explorations Perineales, Paris, France.
245    10
$a Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study / $c G. Amarenco, M. Sutory, R. Zachoval, M. Agarwal, G. Del Popolo, R. Tretter, G. Compion, D. De Ridder,
520    9_
$a AIMS: To investigate the effect on urodynamics of 4 weeks treatment with solifenacin succinate in patients with neurogenic detrusor overactivity (NDO) due to multiple sclerosis (MS) or spinal cord injury (SCI). METHODS: SONIC was a prospective, multicenter, double-blind, phase 3b/4 study investigating the efficacy and safety of solifenacin 10 mg in patients with NDO due to MS or SCI. Patients (n = 189) were randomized to placebo or active treatment (solifenacin 5 mg, 10 mg or oxybutynin hydrochloride 15 mg) for 4 weeks, after a 2-week, single-blind, placebo run-in period. The primary endpoint was change in maximum cystometric capacity (MCC) from baseline to end of treatment. The primary analysis compared solifenacin 10 mg versus placebo; all other comparisons were considered secondary. Secondary endpoints included changes in urodynamic parameters, patient-reported outcomes, and safety assessments. RESULTS: In the primary analysis, solifenacin 10 mg significantly improved mean change from baseline MCC versus placebo (P < 0.001) and was associated with improvements in bladder volume at first contraction and at first leak as well as detrusor pressure at first leak. Similar results were obtained for oxybutynin versus placebo. Patient perception of bladder condition significantly improved with solifenacin 10 mg versus placebo (P = 0.041). There was a clear improvement in quality of life (QoL) in the solifenacin arms versus placebo. The overall incidence of adverse events was low. CONCLUSIONS: In patients with NDO due to MS and SCI, 4 weeks of treatment with solifenacin 10 mg improved urodynamic variables and QoL versus placebo and was well tolerated. Neurourol. Urodynam. 36:414-421, 2017. © 2015 Wiley Periodicals, Inc.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a kvalita života $7 D011788
650    _2
$a solifenacin sukcinát $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000069464
650    _2
$a výsledek terapie $7 D016896
650    _2
$a neurogenní močový měchýř $x farmakoterapie $x patofyziologie $7 D001750
650    _2
$a hyperaktivní močový měchýř $x farmakoterapie $x patofyziologie $7 D053201
650    _2
$a urodynamika $x účinky léků $x fyziologie $7 D014563
650    _2
$a urologické látky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D064804
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sutory, M $u Urological Department of Traumatological Clinic, Traumatological Hospital, School of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Zachoval, R $u Thomayer Hospital and 1st and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Agarwal, M $u Cardiff University and University Hospital of Wales, Cardiff, United Kingdom.
700    1_
$a Del Popolo, G $u Department of Neuro-Urology, Careggi University Hospital, Florence, Italy.
700    1_
$a Tretter, R $u Astellas Pharma Europe, Global Data Science, Leiden, The Netherlands.
700    1_
$a Compion, G $u Department of Medical Affairs, Formerly at Astellas Pharma Europe, Chertsey, United Kingdom.
700    1_
$a De Ridder, D $u Department of Urology, KU Leuven, University Hospitals Leuven, Leuven, Belgium.
773    0_
$w MED00003515 $t Neurourology and urodynamics $x 1520-6777 $g Roč. 36, č. 2 (2017), s. 414-421
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26714009 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180517140822 $b ABA008
999    __
$a ok $b bmc $g 1300996 $s 1014212
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 36 $c 2 $d 414-421 $e 20151229 $i 1520-6777 $m Neurourology and urodynamics $n Neurol. urodyn. (Print) $x MED00003515
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace